Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Having a background in malaria physiology and biochemistry, Markus Winterberg’s research focus is on the interaction between host, pathogen and drug, the metabolism of antimalarial drugs and discovering biomarkers for tropical diseases. Markus aims to use these biomarkers to develop non-invasive, field-based rapid diagnostic tests for tropical diseases that quickly identify pathogens, thereby improving diagnostics and the treatment of patients.

Originally from Germany, I went to Australia for my postdoc. After seven years, I moved to Thailand to work with MORU, and I am now the Head of the Clinical Pharmacology Lab.

My main research focus is proteomics and metabolomics. I use proteomics to find molecules that can be used to identify a disease in a patient. A very common situation in the field is a patient who reports in a hospital with a fever and no other symptoms. A big problem there is to know what the patient actually has. One thing that is commonly done then is to just give an antibiotic, which if it is a viral infection won't do anything. We use mass spectrometry to look for molecules in a sample of a patient to identify the pathogen. We can then tell the GP: this patient has disease XYZ.

What we would like to do with these molecules is to develop a rapid test, something like a pregnancy test where we will be able to just use a little bit of urine sample with a dip stick to give a clear yes/no answer if the patient has the disease or not. You won't need a fancy laboratory, you don't need fancy equipment, you don't usually even need a trained person, a lay person can do it, because it is a clear yes/no result and a very simple process.

For the rapid test, we currently work on scrub typhus, a zoonotic disease transmitted by little chigger mites. The actual pathogen is Orientia tsutsugamushi, a tiny intracellular bacteria commonly found in places where people work in fields - so 'scrub' like the scrubs in the field.
The mites live in eschars on the skin and then transmit the bacteria with their saliva. This disease is one of the common ones like dengue, typhus, murine typhus that comes with fever as main symptom. If the patient has a fever and it turns out to be scrub typhus, after a simple course of antibiotic treatment the patient can usually be cleared of the disease.

Q: How far away are you from developing a rapid test for scrub typhus?

Markus Winterberg: We have identified one peptide form pathogen that is found in the patient's urine. We are currently evaluating at what stage of the infection it appears in the urine. Once that is done, we will look into antibody production and see if we can get a first example of a simple readout test.

Once we have the rapid test established - because the treatment for scrub typhus is usually very simple, it is a simple antibiotic course - that will have a great impact on the affected population because you can easily detect if someone has scrub typhus or not.

The other disease we are working on is malaria. The Clinical Pharmacology Department has almost 70,000 or 80,000 patients' samples from antimalarial clinical trials. We have samples of different time courses with different antimalarials. What we are trying now is to look for a marker in patient plasma that can be used to determine whether someone carries malaria parasites or not and correlate this to the treatment outcome.

Q: Why does your line of work matter and why should we fund it?

MW: Lots of research is done on how you treat the disease, but I think it is also very important to know what the disease actually is so you can treat it properly. It is really important to have a test or a way of telling that a patient has a certain disease, so the research finally will provide a better tool for clinicians, especially in rural settings, to correctly diagnose patients.

Q: Tell me a little bit about the benefits of working at MORU.

MW: Coming from a basic biology background, you often only know the disease from looking in a microscope and a petri dish, and that's how you know the disease. But working here is actually working in the hotspot where it happens: you get to see the patient, you get to see the actual disease and the actual pathogen in a patient's sample. That is something that you normally don't get when you work in an isolated laboratory somewhere looking down your microscope.

Q: You have a simple message one or two sentences to say to people about what you do. What would it be?

MW: You can't always get what you want, but if you try, sometimes you may find you get what you need.

Markus Winterberg

Clinical Pharmacology

Dr Markus Winterberg is Head of Laboratory and a Principal Investigator in MORU's Department of Clinical Pharmacology. The key aspect of his research is 'trop-med-omics', the application of mass spectrometry-based bioanalysis in tropical medicine, particularly using proteomics and metabolomics to identify a disease in a patient.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.